BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29545328)

  • 1. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
    Ren W; Ye X; Su H; Li W; Liu D; Pirmoradian M; Wang X; Zhang B; Zhang Q; Chen L; Nie M; Liu Y; Meng B; Huang H; Jiang W; Zeng Y; Li W; Wu K; Hou Y; Wiman KG; Li Z; Zhang H; Peng R; Zhu S; Pan-Hammarström Q
    Blood; 2018 Jun; 131(24):2670-2681. PubMed ID: 29545328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
    Visentini M; Pica A; D'Ippolito G; Sculco E; La Gualana F; Gragnani L; Miglionico M; Mazzaro C; Fiorilli M; Basili S; Martelli M; Di Rocco A; Casato M; Gentile G; Pulsoni A
    Ann Hematol; 2023 Dec; 102(12):3457-3463. PubMed ID: 37650886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
    N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of diffuse large B-cell lymphoma.
    Pasqualucci L; Dalla-Favera R
    Blood; 2018 May; 131(21):2307-2319. PubMed ID: 29666115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yamaguchi M; Suzuki R; Oguchi M
    Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A licensing step links AID to transcription elongation for mutagenesis in B cells.
    Methot SP; Litzler LC; Subramani PG; Eranki AK; Fifield H; Patenaude AM; Gilmore JC; Santiago GE; Bagci H; Côté JF; Larijani M; Verdun RE; Di Noia JM
    Nat Commun; 2018 Mar; 9(1):1248. PubMed ID: 29593215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anaplastic T-cell lymphoma mimicking classical Hodgkin lymphoma.
    Wang HY; Jaffe ES
    Blood; 2018 Mar; 131(11):1262. PubMed ID: 29545405
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.
    Puente XS; Jares P; Campo E
    Blood; 2018 May; 131(21):2283-2296. PubMed ID: 29666114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory Hodgkin lymphoma: time for targeted therapies?
    Brice P
    Blood; 2018 Mar; 131(11):1156-1157. PubMed ID: 29545402
    [No Abstract]   [Full Text] [Related]  

  • 11. Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.
    Nguyen KA; Su C; Bai HX; Zhang Z; Xiao R; Karakousis G; Zhang PJ; Zhang G
    Br J Haematol; 2018 Apr; 181(2):196-204. PubMed ID: 29602182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.
    Pillonel V; Juskevicius D; Ng CKY; Bodmer A; Zettl A; Jucker D; Dirnhofer S; Tzankov A
    Leukemia; 2018 Nov; 32(11):2412-2426. PubMed ID: 29556019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical influences on the pathogenesis of follicular lymphoma.
    Küppers R; Stevenson FK
    Blood; 2018 May; 131(21):2297-2306. PubMed ID: 29666116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.
    Bellei M; Foss FM; Shustov AR; Horwitz SM; Marcheselli L; Kim WS; Cabrera ME; Dlouhy I; Nagler A; Advani RH; Pesce EA; Ko YH; Martinez V; Montoto S; Chiattone C; Moskowitz A; Spina M; Biasoli I; Manni M; Federico M;
    Haematologica; 2018 Jul; 103(7):1191-1197. PubMed ID: 29599200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
    Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M
    Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell tumor development in
    Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
    Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic markers of viral infection and risk of non-Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore.
    Bassig BA; Willhauck-Fleckenstein M; Shu XO; Koh WP; Gao YT; Purdue MP; Xiang YB; Adams-Haduch J; Wang R; Brenner N; Waterboer T; Michel A; Ji BT; Hosgood HD; Rabkin CS; Yang G; Wong JYY; Zhang J; Hu W; Seow WJ; Chow WH; Pawlita M; Zheng W; Yuan JM; Lan Q; Rothman N
    Int J Cancer; 2018 Aug; 143(3):570-579. PubMed ID: 29574937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Araf S; Wang J; Korfi K; Pangault C; Kotsiou E; Rio-Machin A; Rahim T; Heward J; Clear A; Iqbal S; Davies JK; Johnson P; Calaminici M; Montoto S; Auer R; Chelala C; Gribben JG; Graham TA; Fest T; Fitzgibbon J; Okosun J
    Leukemia; 2018 May; 32(5):1261-1265. PubMed ID: 29568095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.